Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs ASA for Thromboembolism Prevention in Multiple Myeloma (RithMM)
NCT03428373Phase 3Active, not recruiting
- Start
- Jan 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rivaroxaban in venous thromboembolism (VTE), arterial thromboembolism. Started Jan 2019; status: active, not recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)arterial thromboembolism
Beyond the preview
Go deeper on NCT03428373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03428373.